Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its bumpy ride over recent months. The San Francisco, CA-based health and ...

Hims & Hers Health ($HIMS) stock recently earned a new Buy rating from Barclays at a price target of $48. Barclays sees ...

Hims & Hers Health stock has seen its fair value estimate trimmed from about $46.00 to roughly $44.36 per share, even as analysts grow more optimistic about its long term revenue trajectory. Stronger ...

Hims & Hers shows platform expansion, verticalization, new Labs offerings, slower FCF growth and strong long-term revenue targets. Learn why HIMS stock is a buy.

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock rose 3.6% Thursday after the company announced its official expansion into the Canadian market, marking a significant step in its international ...

Hims & Hers is set to acquire YourBio Health, adding bladeless microneedle tech to transform the blood collection experience.

Virtual healthcare platforms are redefining patient access to care, with Hims & Hers Health, Inc. HIMS and GoodRx Holdings, Inc. GDRX among the leaders in this digital shift. HIMS is a ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

Shares of Hims & Hers are trending Thursday morning. The San Francisco-based telehealth company announced an international ...

Hims & Hers agrees to acquire YourBio Health, adding painless microneedle blood-sampling tech and expanding its at-home testing capabilities ahead of an early-2026 close.